STRAP在人脑胶质瘤组织中的表达及临床意义

目的 探讨人脑胶质瘤组织丝氨酸-苏氨酸激酶受体相关蛋白（STRAP）的表达变化及临床意义。方法 选取2013年6月至2016年9月手术切除的胶质瘤组织160例，术前均未接受过放化疗或免疫治疗；另选取2018年6月~2019年3月颅脑损伤内减压术中切除的正常脑组织40例为对照。采用免疫组化法检测STRAP的表达水平。随访时间截止至2018年10月，采用多因素Cox比例回归风险模型分析胶质瘤病人生存期的影响因素。结果 胶质瘤组织STRAP表达水平明显高于正常脑组织（P<0.05），而且随胶质瘤分级增高，STRAP表达水平明显增高（P<0.05）。160例随访3~60个月，随访期间死亡48例，复发98例。OS在3~58个月，中位OS为43个月（四分间距在36~51个月）。PFS在2~60个月，中位PFS为32个月（四分间距在18~40个月）。多因素Cox比例回归风险模型分析显示，年龄≥55岁、术前KPS评分<80分、WHO分级为Ⅲ~Ⅳ级、STRAP高表达是胶质瘤病人无进展生存期（FPS）和总体生存期（OS）较短的独立影响因素（P<0.05）。与低表达组相比，高表达组胶质瘤病人的PFS和OS明显较短（P<0.05）。结论 STRAP高表达与胶质瘤病人不良生存预后有关，这提示其可能成为胶质瘤的分子标志物

Expression of serine threonine kinase receptor associated protein in human glioma tissues and its clinical significance

Objective To explore the changes of expression of serine-threonine kinase receptor associated protein (STRAP) in human glioma tissues and its clinical significance. Methods The expression levels of STRAP were detected by immunohistochemistry in glioma tissues which were obtained from 160 patients with glioma underwent surgery from June 2013 to September 2016 and in normal brain tissues obtained from 40 patients with traumatic brain injury underwent decompression from June 2018 to March 2019. The follow-up period ended in October 2018. The multivariate Cox proportional regression risk model was used to analyze the risk factors for the survival of glioma patients. Results The expression level of STRAP in glioma tissues was significantly higher than that in normal brain tissues (P<0.05), and the expression level of STRAP increased significantly as the WHO grade of glioma increased (P<0.05). The follow-up ranged from 3 to 60 months. During the follow-up period, 48 aptients died and 98 patients relapsed. The OS ranged 3 to 58 months, and the median OS was 43 months (interquartile, 36~51 months). The PFS ranged from 2 to 60 months, and the median PFS was 32 months (interquartile, 18~40 months). Multivariate Cox proportional regression risk model analysis showed that age≥55 years, preoperative KPS score<80 points, WHO grade Ⅲ to Ⅳ, high expression of STRAP were independent influencing factors for the progression-free survival (FPS) and overall survival (OS) of glioma patients (P<0.05). Compared with the glioma patients with low expression of STRAP, the PFS and OS of glioma patients with high expression were significantly shorter (P<0.05). Conclusion The high expression of STRAP is related to the poor survival and prognosis of patients with glioma, which suggests that it may be a molecular marker of glioma